Evonik’s Russian joint venture OOO DESTEK celebrates ten years of success
The Acrylic Polymers Business Line of Evonik Industries AG began producing extruded PLEXIGLAS® solid sheets in Russia ten years ago and has been increasing its market share in the country ever since. "Having a local presence was crucial if we were to strengthen our business in Russia’s growth market and continue to expand," said Michael Träxler, Head of the Acrylic Polymers Business Line at Evonik. Evonik entered this market through the OOO DESTEK joint venture, in which it has a majority interest. DESTEK supplies the Russian market with several thousand metric tons of extruded PLEXIGLAS® per year. Its main customers are from the illuminated advertising, noise protection, and furniture construction industries.
Evonik has marked the successful ten-year cooperation in the joint venture on May 19 with a ceremony at the DESTEK site in Podolsk (greater Moscow area).
DESTEK has an outstanding distribution network that ensures supplies to the entire Russian market. In response to the strong demand for high-quality PLEXIGLAS® products, Evonik started to expand production capacity back in 2009. "In doing so, we advanced our growth strategy in Russia, further increased the availability of our products, and shortened delivery times," explained Andrey Ivanov, Director General of DESTEK. Currently, more than 30 employees in Podolsk manufacture solid extruded sheets. DESTEK also offers specialty PLEXIGLAS® products from other sites in the global production network of the Acrylic Polymers Business Line. To market these more effectively in Russia, Evonik opened a light studio in Podolsk in 2013 in which customers can see all of the benefits of PLEXIGLAS® for themselves.
Evonik Industries is a worldwide manufacturer of PMMA products sold under the PLEXIGLAS® trademark on the European, Asian, African and Australian continents and under the ACRYLITE® trademark in the Americas.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.